Printer Friendly

BELLINGHAM INDUSTRIES ACQUIRES 24.1 PERCENT OF THERAGENICS

       BELLINGHAM INDUSTRIES ACQUIRES 24.1 PERCENT OF THERAGENICS
    ATLANTA, Dec. 17 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX) announced today that Bellingham Industries, a Panamanian investment firm, had acquired a 24.1 percent interest in the company.
    The acquisition, which totaled 2,383,500 shares of Theragenics common stock, took place Dec. 3 on the London Stock Exchange.  Today's announcement on the purchase was made in compliance with the obligatory 14-day waiting period following filing of the 13d.
    Principals of Bellingham were all citizens of the United Kingdom.
    Theragenics President and CEO John V. Herndon said he was "extremely pleased" that an international investment concern had taken a strong financial position in his company.  He said he believed that Theragenics' strong performance during the past three quarters as well as the company's rapid expansion of its customer base had all been "attractive elements in bringing us to the attention of the international investment community."
    The company has been profitable for each of the last three quarters and has increased its client list by nearly 50 percent during that same period.
    Theragenics is a cancer therapy company based in Atlanta.  The company's leading product, TheraSeed, is a nonsurgical, outpatient treatment which uses implanted Palladium 103 seeds to eradicate prostate cancer.  The product is now used at more than 90 clinics and hospitals nationwide.
    -0-         12/17/91
    /CONTACT:  Bruce Smith, chief financial officer of Theragenics, 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
    (THRX) CO:  Theragenics Corp.; Bellingham Industries ST:  Georgia IN:  MTC SU: FC-TS -- NY011 -- 2830 12/17/91 09:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1991
Words:262
Previous Article:BARNETT GAINS LARGEST SHARE OF NEW DEPOSITS
Next Article:LASERMASTER TECHNOLOGIES ANNOUNCES SALES AGREEMENT WITH AM MULTIGRAPHICS
Topics:


Related Articles
THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT
THERAGENICS ACHIEVES RECORD REVENUES AND EARNINGS FOR FIRST QUARTER OF 1992
THERAGENICS RAISES $3 MILLION IN PRIVATE PLACEMENT
THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O.
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters